ARROWHEAD'S 3rd Annual Traumatic Brain Injury Conference is bringing researchers, clinicians in industry, academia and the military, and regulators together to discuss how best to achieve the goal of bringing new therapies to market for TBI. In order to do so, there is a strong need for consensus regarding the following key questions at this year's conference:
How can animal model results translate to clinical research?
What are the key patient populations for future clinical trials?
What outcomes should new clinical trials measure?
How can the blood-brain barrier be overcome in drug delivery?
How can companion diagnostics and biomarkers improve therapeutic interventions and outcome prediction?
What are the regulatory barriers facing developers of both companion diagnostics and new therapies?